Review



rcgd 423  (Tocris)


Bioz Verified Symbol Tocris is a verified supplier
Bioz Manufacturer Symbol Tocris manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Tocris rcgd 423
    Rcgd 423, supplied by Tocris, used in various techniques. Bioz Stars score: 90/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rcgd+423/RCGD+423/us11247974-1458-25-39
    Average 90 stars, based on 2 article reviews
    rcgd 423 - by Bioz Stars, 2026-09
    90/100 stars

    Images

    Related Articles

    Incubation:

    Article Title: Small molecules that enable cartilage rejuvenation
    Article Snippet: Migration Assay.Migration Assay.. Cells were plated on Millicell 8 μm Transwell® inserts (Millipore, Billerica, Mass.) in 12-well plates (Fisher Scientific, Pittsburgh, Pa.) and stimulated with 10 μM of RCGD 423, 10 μM MYC inhibitor (10058-F4) or 10 μM STAT3 inhibitor (STATTIC) from Tocris Bioscience (Bristol, UK).. Cells that migrated across the membranes were quantified by counting after 48 hours of treatment.Cells that migrated across the membranes were quantified by counting after 48 hours of treatment.

    Article Title: Small molecules that enable cartilage rejuvenation
    Article Snippet: Migration Assay.Migration Assay.. Cells were plated on Millicell 8 μm Transwell® inserts (Millipore, Billerica, Mass.) in 12-well plates (Fisher Scientific, Pittsburgh, Pa.) and stimulated with 10 μM of RCGD 423, 10 μM MYC inhibitor (10058-F4) or 10 μM STAT3 inhibitor (STATTIC) from Tocris Bioscience (Bristol, UK).. Cells that migrated across the membranes were quantified by counting after 48 hours of treatment.Cells that migrated across the membranes were quantified by counting after 48 hours of treatment.



    Similar Products

    rcgd 423  (Tocris)
    90
    Tocris rcgd 423
    Rcgd 423, supplied by Tocris, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rcgd+423/RCGD+423/us11247974-1458-25-39
    Average 90 stars, based on 1 article reviews
    rcgd 423 - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    rcgd 423 n-(4-bromophenyl)-4-phenyl-1,3-thiazol-2-amine  (MolPort Inc)
    90
    MolPort Inc rcgd 423 n-(4-bromophenyl)-4-phenyl-1,3-thiazol-2-amine
    Rcgd 423 N (4 Bromophenyl) 4 Phenyl 1,3 Thiazol 2 Amine, supplied by MolPort Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rcgd+423/rcgd+423+n++4+bromophenyl++4+phenyl+1+3+thiazol+2+amine/us11247974-1401-0-8
    Average 90 stars, based on 1 article reviews
    rcgd 423 n-(4-bromophenyl)-4-phenyl-1,3-thiazol-2-amine - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    rcgd 423  (Mebiol Inc)
    90
    Mebiol Inc rcgd 423
    Rcgd 423, supplied by Mebiol Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rcgd+423/rcgd+423/us11247974-1404-14-20
    Average 90 stars, based on 1 article reviews
    rcgd 423 - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    rcgd423  (Tocris)
    91
    Tocris rcgd423
    Conversion of RAW264.7 pre-osteoclasts into iTS cells by the treatment with BML284. CN = control, CM = conditioned medium, RAW = RAW264.7 osteoclasts, MC3T3 = MC3T3 osteoblasts, MSC = mesenchymal stem cells, A5 = MLO-A5 osteocytes, 231 = MDA-MB-231 breast cancer cells, EO = EO771 mammary tumor cells, and 4T1.2 = 4T1.2 mammary tumor cells. ** p < 0.01 vs. CN, while ## p < 0.01 vs. A5 CM. ( A – D ) MTT-based viability of EO771 mammary tumor cells in response to a chemically treated conditioned medium, derived from MLO-A5 osteocytes, MSCs, MC3T3 osteoblasts, and RAW264.7 osteoclasts, respectively. NS = NSC228155 (EGF activator), RC = <t>RCGD423</t> (JAK/STAT activator), m3 = m-3M3FBS (phospholipase C activator), CW = CW008 (PKA activator), OA = OAC2 (Oct4 activator), YS = YS49 (PI3K activator), and BM = BML284 (Wnt activator). ( E , F ) Tumor selectivity of the inhibitory action of RAW CM, examined tumor selectivity of the inhibitory action using 3 tumor cell lines (MDA-MB-231 breast cancer cell line using 3 tumor cell lines (MDA-MB-231 breast cancer cell line, EO771 mammary tumor cell line, and 4T1.2 mammary tumor cell line), and KTB6 human breast epithelial cells. ( G ) Reduction in PTHrP in BM CM.
    Rcgd423, supplied by Tocris, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rcgd+423/RCGD+423/pmc08615769-51-25-26
    Average 91 stars, based on 1 article reviews
    rcgd423 - by Bioz Stars, 2026-09
    91/100 stars
    		  Buy from Supplier
    rcgd 423 (n-(4-bromophenyl)-4-phenyl-1,3-thiazol-2-amine  (MolPort Inc)
    90
    MolPort Inc rcgd 423 (n-(4-bromophenyl)-4-phenyl-1,3-thiazol-2-amine
    Conversion of RAW264.7 pre-osteoclasts into iTS cells by the treatment with BML284. CN = control, CM = conditioned medium, RAW = RAW264.7 osteoclasts, MC3T3 = MC3T3 osteoblasts, MSC = mesenchymal stem cells, A5 = MLO-A5 osteocytes, 231 = MDA-MB-231 breast cancer cells, EO = EO771 mammary tumor cells, and 4T1.2 = 4T1.2 mammary tumor cells. ** p < 0.01 vs. CN, while ## p < 0.01 vs. A5 CM. ( A – D ) MTT-based viability of EO771 mammary tumor cells in response to a chemically treated conditioned medium, derived from MLO-A5 osteocytes, MSCs, MC3T3 osteoblasts, and RAW264.7 osteoclasts, respectively. NS = NSC228155 (EGF activator), RC = <t>RCGD423</t> (JAK/STAT activator), m3 = m-3M3FBS (phospholipase C activator), CW = CW008 (PKA activator), OA = OAC2 (Oct4 activator), YS = YS49 (PI3K activator), and BM = BML284 (Wnt activator). ( E , F ) Tumor selectivity of the inhibitory action of RAW CM, examined tumor selectivity of the inhibitory action using 3 tumor cell lines (MDA-MB-231 breast cancer cell line using 3 tumor cell lines (MDA-MB-231 breast cancer cell line, EO771 mammary tumor cell line, and 4T1.2 mammary tumor cell line), and KTB6 human breast epithelial cells. ( G ) Reduction in PTHrP in BM CM.
    Rcgd 423 (N (4 Bromophenyl) 4 Phenyl 1,3 Thiazol 2 Amine, supplied by MolPort Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rcgd+423/rcgd+423+n++4+bromophenyl++4+phenyl+1+3+thiazol+2+amine/us11072592-1303-0-8
    Average 90 stars, based on 1 article reviews
    rcgd 423 (n-(4-bromophenyl)-4-phenyl-1,3-thiazol-2-amine - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Conversion of RAW264.7 pre-osteoclasts into iTS cells by the treatment with BML284. CN = control, CM = conditioned medium, RAW = RAW264.7 osteoclasts, MC3T3 = MC3T3 osteoblasts, MSC = mesenchymal stem cells, A5 = MLO-A5 osteocytes, 231 = MDA-MB-231 breast cancer cells, EO = EO771 mammary tumor cells, and 4T1.2 = 4T1.2 mammary tumor cells. ** p < 0.01 vs. CN, while ## p < 0.01 vs. A5 CM. ( A – D ) MTT-based viability of EO771 mammary tumor cells in response to a chemically treated conditioned medium, derived from MLO-A5 osteocytes, MSCs, MC3T3 osteoblasts, and RAW264.7 osteoclasts, respectively. NS = NSC228155 (EGF activator), RC = RCGD423 (JAK/STAT activator), m3 = m-3M3FBS (phospholipase C activator), CW = CW008 (PKA activator), OA = OAC2 (Oct4 activator), YS = YS49 (PI3K activator), and BM = BML284 (Wnt activator). ( E , F ) Tumor selectivity of the inhibitory action of RAW CM, examined tumor selectivity of the inhibitory action using 3 tumor cell lines (MDA-MB-231 breast cancer cell line using 3 tumor cell lines (MDA-MB-231 breast cancer cell line, EO771 mammary tumor cell line, and 4T1.2 mammary tumor cell line), and KTB6 human breast epithelial cells. ( G ) Reduction in PTHrP in BM CM.

    Journal: Cancers

    Article Title: Conversion of Osteoclasts into Bone-Protective, Tumor-Suppressing Cells

    doi: 10.3390/cancers13225593

    Figure Lengend Snippet: Conversion of RAW264.7 pre-osteoclasts into iTS cells by the treatment with BML284. CN = control, CM = conditioned medium, RAW = RAW264.7 osteoclasts, MC3T3 = MC3T3 osteoblasts, MSC = mesenchymal stem cells, A5 = MLO-A5 osteocytes, 231 = MDA-MB-231 breast cancer cells, EO = EO771 mammary tumor cells, and 4T1.2 = 4T1.2 mammary tumor cells. ** p < 0.01 vs. CN, while ## p < 0.01 vs. A5 CM. ( A – D ) MTT-based viability of EO771 mammary tumor cells in response to a chemically treated conditioned medium, derived from MLO-A5 osteocytes, MSCs, MC3T3 osteoblasts, and RAW264.7 osteoclasts, respectively. NS = NSC228155 (EGF activator), RC = RCGD423 (JAK/STAT activator), m3 = m-3M3FBS (phospholipase C activator), CW = CW008 (PKA activator), OA = OAC2 (Oct4 activator), YS = YS49 (PI3K activator), and BM = BML284 (Wnt activator). ( E , F ) Tumor selectivity of the inhibitory action of RAW CM, examined tumor selectivity of the inhibitory action using 3 tumor cell lines (MDA-MB-231 breast cancer cell line using 3 tumor cell lines (MDA-MB-231 breast cancer cell line, EO771 mammary tumor cell line, and 4T1.2 mammary tumor cell line), and KTB6 human breast epithelial cells. ( G ) Reduction in PTHrP in BM CM.

    Article Snippet: RAW264.7 pre-osteoclast cells, MC3T3 osteoblasts, MSCs, and MLO-A5 osteocyte-like cells were treated with 0.5 μM of NSC228155 (Cayman, Ann Arbor, MI, USA), 20 μM of RCGD423 (Tocris, Minneapolis, MN, USA), 20 μM of m-3M3FBS (Tocris), 20 μM of CW008 (Tocris), 10 μM of OAC2 (MCE, Monmouth Junction, NJ, USA), 50μM of YS49 (MCE), and 0.2 μM of BML284 (Santa Cruz Biotechnology, Dallas, TX, USA) for 1 day.

    Techniques: Control, Derivative Assay